US.GILD · Gilead Sciences

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.3329189973068156,
        "turnoverUsdM": 826.50321981,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.GILD",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 138.0534,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 4.7,
      "take_profit_price": 152.4055,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 5.2
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.665837994613631,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 53.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 48.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 145.9675,
    "ma50": 137.7352,
    "close": 144.81,
    "prevClose": 145.65,
    "avgVolume20": 5288115,
    "volumeRatio": 1.08,
    "changePercent": -0.58
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": -0.032083416883898264,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 1.0795491901727468,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 0.6789072656648301,
      "volat_points": 0,
      "day_range_pct": 0.015445065948484289,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 53.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 5.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 36,
        "contribution": 5.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 17.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 57.67,
        "contribution": 17.3
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 48.6,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 5.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 17.3/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.5,
      "資金流": 10,
      "市場環境": 5.4,
      "情緒分析": 4,
      "技術信號": 17.3,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0.6,
          "roePoints": 0,
          "debtPoints": 0.3,
          "marginPoints": 0,
          "turnoverUsdM": 826.50321981,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 4,
          "mfiPoints": 2.4,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.GILD",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.3329189973068156,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142064080,
                "url": "https://finnhub.io/api/news?id=da346412b0924987fc8149acf6d8b919f0810f634749adc1d3bf703be47da8d5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (GILD) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 10:55 AM EDTCompany ParticipantsAndrew Dickinson...",
                "category": "company",
                "datetime": 1789051030,
                "headline": "Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript"
              },
              {
                "id": 142042913,
                "url": "https://finnhub.io/api/news?id=000bbdddc3ad703573afb7b40f14a201dac9da3b9e278fe91f9f07c277b06431",
                "image": "",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "",
                "category": "company",
                "datetime": 1789007226,
                "headline": "Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141956274,
                "url": "https://finnhub.io/api/news?id=76fab93bf354f97540350803ce18fdd241dd3bc4402e70b95b0cd130daad5d21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.",
                "category": "company",
                "datetime": 1788904203,
                "headline": "Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights"
              },
              {
                "id": 141446730,
                "url": "https://finnhub.io/api/news?id=97438cf3f88abe64d70c7500bf824951470d89577dd7917d3130081bb49f9324",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...",
                "category": "company",
                "datetime": 1788541707,
                "headline": "Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?"
              },
              {
                "id": 141416319,
                "url": "https://finnhub.io/api/news?id=7847eb499abd84cb6b2a197b92248d71b3f1a485f4da5c697699284f8448b71a",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences offers a 3.98% dividend yield backed by strong profitability and a solid track record, meeting key quality, health, and income criteria.",
                "category": "company",
                "datetime": 1788517262,
                "headline": "Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors"
              },
              {
                "id": 141400446,
                "url": "https://finnhub.io/api/news?id=cdbc5a2b8ff74d546c660d56825b641d1ba0c356cd2404e5938aade463184630",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449413,
                "headline": "Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?"
              },
              {
                "id": 141369972,
                "url": "https://finnhub.io/api/news?id=e715ef333fe0f10a5be90c0f4faee9b2cbcee1ed9c1942455ee6e0cc33bc830d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).",
                "category": "company",
                "datetime": 1788282004,
                "headline": "Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?"
              },
              {
                "id": 141361765,
                "url": "https://finnhub.io/api/news?id=3625807e3b7d9ffd0384a81c7dd411557e74cd8dd79db9ae9e73809a2d7acbe9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
                "category": "company",
                "datetime": 1788273004,
                "headline": "Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?"
              }
            ],
            "raw_source": [
              {
                "id": 142063365,
                "url": "https://finnhub.io/api/news?id=0ed67144a68bc840d272b72df6b3c43cc6e656d69f74fb58b365fa026d5ce8d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy. Dickinson said the",
                "category": "company",
                "datetime": 1789056176,
                "headline": "Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth"
              },
              {
                "id": 142064080,
                "url": "https://finnhub.io/api/news?id=da346412b0924987fc8149acf6d8b919f0810f634749adc1d3bf703be47da8d5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (GILD) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 10:55 AM EDTCompany ParticipantsAndrew Dickinson...",
                "category": "company",
                "datetime": 1789051030,
                "headline": "Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript"
              },
              {
                "id": 142060842,
                "url": "https://finnhub.io/api/news?id=6aaadd0e7e9b970cceffe7dadb4bbfb905b69b38f5f0e06fa615665bc5040747",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.",
                "category": "company",
                "datetime": 1789048260,
                "headline": "Here's Why You Should Add NRIX Stock to Your Portfolio Now"
              },
              {
                "id": 142063995,
                "url": "https://finnhub.io/api/news?id=2114b9eff9d26517a18cb17a74102d3799b673b416699a70e7ed2d6275618cfd",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "HSBC  analyst Morten Herholdt   maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.",
                "category": "company",
                "datetime": 1789034133,
                "headline": "HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175"
              },
              {
                "id": 142038766,
                "url": "https://finnhub.io/api/news?id=abf077c057e43a990b139d1ead57ad083e16fd7cdf95129e2aea49a96b2f2939",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizat",
                "category": "company",
                "datetime": 1789012923,
                "headline": "Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode"
              },
              {
                "id": 142042913,
                "url": "https://finnhub.io/api/news?id=000bbdddc3ad703573afb7b40f14a201dac9da3b9e278fe91f9f07c277b06431",
                "image": "",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "",
                "category": "company",
                "datetime": 1789007226,
                "headline": "Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142026021,
                "url": "https://finnhub.io/api/news?id=8594abe1497fc9106ab538c18da2afa5b36087b9d3b0a4028a4f1f1878bc3195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.",
                "category": "company",
                "datetime": 1788966840,
                "headline": "Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?"
              },
              {
                "id": 142026022,
                "url": "https://finnhub.io/api/news?id=a0f5c5fb0aef924dac915b794d5abb1c497932d0ce5a4233e63e04460a45eb11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "MENLO PARK, Calif., September 09, 2026--Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner",
                "category": "company",
                "datetime": 1788966000,
                "headline": "Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner"
              },
              {
                "id": 142024797,
                "url": "https://finnhub.io/api/news?id=edd9ed0b8d353ab5c40edb953531b96c2e83f621f912c8284ee9134fa5016c74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
                "category": "company",
                "datetime": 1788962078,
                "headline": "1 S&P 500 Stock on Our Buy List and 2 Facing Challenges"
              },
              {
                "id": 142023979,
                "url": "https://finnhub.io/api/news?id=304c041e173532a7de2485f8d132ef35a7fe15c29f2d746df0965b686b1d8407",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The new research centre is part of Gilead's strategy to advance US research, development and manufacturing through 2030.",
                "category": "company",
                "datetime": 1788951565,
                "headline": "Gilead launches research facility in US for new medicine development"
              },
              {
                "id": 142025172,
                "url": "https://finnhub.io/api/news?id=f47919b23f1416ade31c074dd57b0bf69f46b300135f105f8490b9a26f86e126",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314008084/image_1314008084.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "MacroGenics (MGNX) trades below cash with a strong ADC/TCE pipeline and ESMO 2026 catalysts.",
                "category": "company",
                "datetime": 1788948935,
                "headline": "MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead"
              },
              {
                "id": 141956274,
                "url": "https://finnhub.io/api/news?id=76fab93bf354f97540350803ce18fdd241dd3bc4402e70b95b0cd130daad5d21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.",
                "category": "company",
                "datetime": 1788904203,
                "headline": "Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights"
              },
              {
                "id": 141955148,
                "url": "https://finnhub.io/api/news?id=0868d87bb94fd379211d3a92cf37fd6636eadc854f14b8b83601df794b947e91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it",
                "category": "company",
                "datetime": 1788897600,
                "headline": "Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program"
              },
              {
                "id": 141952666,
                "url": "https://finnhub.io/api/news?id=5886fb16e071251ca774431c1613e530683b2a5a27fa519a9e5ba2a1f4f4b338",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., September 08, 2026--Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines",
                "category": "company",
                "datetime": 1788886800,
                "headline": "Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines"
              },
              {
                "id": 141952209,
                "url": "https://finnhub.io/api/news?id=850de156e14d0c8942f5e85d52c65add5c6a51fbd2de123d0090aba68afd7c3b",
                "image": "https://image.cnbcfm.com/api/v1/image/108359691-17888685481788868546-48249872740-1080pnbcnews.jpg?v=1788868547&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "CNBC’s Annika Kim Constantino reports on the latest news on AstraZeneca.",
                "category": "company",
                "datetime": 1788855516,
                "headline": "AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes"
              },
              {
                "id": 141772062,
                "url": "https://finnhub.io/api/news?id=e9b9d9d31dd726778b52be72a6d625f54d46efac00ffb718b79c28451fb80256",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infection is already suppressed to very low levels. The combination brings together bictegravir, a key component of Gilead’s (NASDAQ:GILD) blockbuster Biktarvy, and lenacapavir, the foundation of the company’s longer-term HIV strategy. […]",
                "category": "company",
                "datetime": 1788828322,
                "headline": "Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?"
              },
              {
                "id": 141771131,
                "url": "https://finnhub.io/api/news?id=54bd7ced710bb8cc5af628a759507a12394f53b813d5d08ed02199f47fabf0b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?",
                "category": "company",
                "datetime": 1788798125,
                "headline": "IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?"
              },
              {
                "id": 141762466,
                "url": "https://finnhub.io/api/news?id=a42a76609a86d006172a30f5fa30fc2eeacbe6927b5951b4499be9174812eb1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "One-Year Analytical Tool Delivers Deal-Grade Competitive Intelligence on 2,370+ Drugs, 1,700+ BD&L Contacts, and 208 Top Investors as the Pipeline Adds 236 New Therapies in Just 12 MonthsDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence\" directory has been added to ResearchAndMarkets.com's offering. The world of CAR/TCR/TIL therapies is transforming cancer treatment, unlocking new levels of precision, i",
                "category": "company",
                "datetime": 1788778020,
                "headline": "Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals"
              },
              {
                "id": 141525565,
                "url": "https://finnhub.io/api/news?id=b9aa53f7980c7850fe32049ca157959b6407864729c833d25e047db0bfc442b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.",
                "category": "company",
                "datetime": 1788621600,
                "headline": "Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?"
              },
              {
                "id": 141446730,
                "url": "https://finnhub.io/api/news?id=97438cf3f88abe64d70c7500bf824951470d89577dd7917d3130081bb49f9324",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...",
                "category": "company",
                "datetime": 1788541707,
                "headline": "Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?"
              },
              {
                "id": 141446731,
                "url": "https://finnhub.io/api/news?id=4b38fd9f0158a3efee896bbf9ff2f4048a0887d19b378fd1d25d2a6bdaa320c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535815,
                "headline": "Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141437466,
                "url": "https://finnhub.io/api/news?id=2cf48ee5dc1edcb99643cb85c3d05072d38361179e602f97172a84082065c24f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.",
                "category": "company",
                "datetime": 1788533151,
                "headline": "Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?"
              },
              {
                "id": 141416319,
                "url": "https://finnhub.io/api/news?id=7847eb499abd84cb6b2a197b92248d71b3f1a485f4da5c697699284f8448b71a",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences offers a 3.98% dividend yield backed by strong profitability and a solid track record, meeting key quality, health, and income criteria.",
                "category": "company",
                "datetime": 1788517262,
                "headline": "Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors"
              },
              {
                "id": 141431623,
                "url": "https://finnhub.io/api/news?id=54f9adcca01797caf62d176be528d4231ee39624524110f876fdc2dce347ce22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.",
                "category": "company",
                "datetime": 1788516658,
                "headline": "Gilead’s growing HIV franchise; cell therapy licensing deals plummet"
              },
              {
                "id": 141400446,
                "url": "https://finnhub.io/api/news?id=cdbc5a2b8ff74d546c660d56825b641d1ba0c356cd2404e5938aade463184630",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449413,
                "headline": "Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?"
              },
              {
                "id": 141401724,
                "url": "https://finnhub.io/api/news?id=e172db1f2c3229e3332feba846b3a0d130425291f1429f41071e1891d84adf67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.",
                "category": "company",
                "datetime": 1788432984,
                "headline": "Is Gilead Sciences Stock Outperforming the S&P 500?"
              },
              {
                "id": 141379511,
                "url": "https://finnhub.io/api/news?id=8780cdd6f1f1fad15e05dfd24f46c854de4ccc02b6ab97af39ced883123d9239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.",
                "category": "company",
                "datetime": 1788361620,
                "headline": "Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?"
              },
              {
                "id": 141373188,
                "url": "https://finnhub.io/api/news?id=7ce10bb0e2769a3b655fc5b7d8513360ee1d62dff5e06852786e47715d74277a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Toyota Motor's hybrid growth and expanded value-chain businesses support demand, but higher costs, China weakness and leverage temper prospects.",
                "category": "company",
                "datetime": 1788298740,
                "headline": "Top Research Reports for Toyota Motor, CrowdStrike & Welltower"
              },
              {
                "id": 141369874,
                "url": "https://finnhub.io/api/news?id=d712d75c450835888382f0049c3dfaaa54fd8760a7b25a62dc9c11038231ace7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.",
                "category": "company",
                "datetime": 1788291120,
                "headline": "Can Bixlenvo Unlock New Growth for Gilead's HIV Business?"
              },
              {
                "id": 141369972,
                "url": "https://finnhub.io/api/news?id=e715ef333fe0f10a5be90c0f4faee9b2cbcee1ed9c1942455ee6e0cc33bc830d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).",
                "category": "company",
                "datetime": 1788282004,
                "headline": "Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?"
              },
              {
                "id": 141361765,
                "url": "https://finnhub.io/api/news?id=3625807e3b7d9ffd0384a81c7dd411557e74cd8dd79db9ae9e73809a2d7acbe9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
                "category": "company",
                "datetime": 1788273004,
                "headline": "Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?"
              },
              {
                "id": 141361469,
                "url": "https://finnhub.io/api/news?id=34e30cd031c810d63415f91661c6455830424a81e544234aa232e3fa4a773e73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1788194343,
                "headline": "Cocrystal Pharma: The Strategic Reset Investors May Be Missing"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141361774,
                "url": "https://finnhub.io/api/news?id=35a53082f64df48c62863686b7a5c8f6e6033194aac9d823f3dacb5c569b7cf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1788185424,
                "headline": "3 Unpopular Stocks with Open Questions"
              },
              {
                "id": 141356311,
                "url": "https://finnhub.io/api/news?id=d9c36644c7e7ab3bd5d32c12e2a4520092e767088ff9071a6bedb9aa3bd368de",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/31/Boston--Massachusetts-July-7--2017--Hold.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV.",
                "category": "company",
                "datetime": 1788183490,
                "headline": "FDA Approves Gilead's New Single Tablet HIV Regimen"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141361775,
                "url": "https://finnhub.io/api/news?id=cb2f3998c16eb9009dd720555aed84db297ffe6737ab8800383c5199e803eb0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.",
                "category": "company",
                "datetime": 1787931660,
                "headline": "Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection"
              },
              {
                "id": 141361776,
                "url": "https://finnhub.io/api/news?id=82a7fd3310aa78a371e6fe072981ad7b7cfa708c1bc9680b66baa459bdb6d883",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.",
                "category": "company",
                "datetime": 1787921940,
                "headline": "Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines"
              },
              {
                "id": 141338793,
                "url": "https://finnhub.io/api/news?id=bd81a66323ddaec8a6c063ad55e9bab105eb706d36589a0de58b89f58003aded",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report",
                "category": "company",
                "datetime": 1787921002,
                "headline": "World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency"
              },
              {
                "id": 141361766,
                "url": "https://finnhub.io/api/news?id=854ac346fe32678509db07f8a0fb6098a7b48775574ce24224511e0be48ce466",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences has delivered strong share price gains over the past five years, yet based on broad valuation checks it still screens as inexpensive relative to its fundamentals. For investors, the stock now sits in an interesting spot where a powerful HIV and oncology franchise is reflected in the price to some extent, but the broader valuation read still points to room for a more optimistic view than the market currently implies. Over the past 5 years, Gilead Sciences has returned about...",
                "category": "company",
                "datetime": 1787872523,
                "headline": "Gilead (GILD) Stock Looks Undervalued After A 147% Five Year Run"
              },
              {
                "id": 141361767,
                "url": "https://finnhub.io/api/news?id=bc1bface364cf536a790f0946c9efe832c5e85714ed796d5f4150f99afd7403e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., August 27, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs.",
                "category": "company",
                "datetime": 1787870820,
                "headline": "U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens"
              },
              {
                "id": 141332704,
                "url": "https://finnhub.io/api/news?id=5433b90d434ccadf5fa25840410d7ff01912ef51cbc03381fbdc7a0328c91add",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.",
                "category": "company",
                "datetime": 1787864703,
                "headline": "What's going on in today's after hours session: S&P500 movers"
              },
              {
                "id": 141338646,
                "url": "https://finnhub.io/api/news?id=ac46f1581981d738f253d21452b238c9e68d01e58945e3ab57ce497db1a1ee4b",
                "image": "https://image.cnbcfm.com/api/v1/image/108355488-17878677491787867746-48024014170-1080pnbcnews.jpg?v=1787867748&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "CNBC's Annika Kim Constantino reports on the FDA's decision to approve Gilead's daily HIV pill.",
                "category": "company",
                "datetime": 1787853564,
                "headline": "FDA approves Gilead's daily HIV pill"
              },
              {
                "id": 141338456,
                "url": "https://finnhub.io/api/news?id=8bc05d08a8005d74d42a38241764750117a10a3407aa06e52223dc69ad60e058",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the",
                "category": "company",
                "datetime": 1787853265,
                "headline": "Gilead Sciences Announces FDA Approval For Bixlenvo, The Smallest Once-Daily Single Tablet Regimen For The Treatment Of HIV In Adults Who Are Virologically Suppressed"
              },
              {
                "id": 141338647,
                "url": "https://finnhub.io/api/news?id=13070209ef1489d5f37ffc15f8df725ce0c53e058542fba2c275331cd8308ca6",
                "image": "https://image.cnbcfm.com/api/v1/image/108355149-1787838771893-Untitled-1.jpg?v=1787838821&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.",
                "category": "company",
                "datetime": 1787852958,
                "headline": "FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients"
              },
              {
                "id": 141361768,
                "url": "https://finnhub.io/api/news?id=94d7df552f1cc860119be93e60531ba67f87ea6e557114f77e22373084fdbb04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) is back in focus after the European Commission approved Trodelvy plus Keytruda for certain first line metastatic triple negative breast cancer patients, expanding the company’s oncology franchise in Europe. For investors tracking the bigger picture, Gilead Sciences’ 1 month share price return of 10.25% and year to date share price return of 21.78% point to firming momentum. The 1 year total shareholder return of 34.99% and 5 year total shareholder return of 145.70%...",
                "category": "company",
                "datetime": 1787836483,
                "headline": "Gilead Sciences (GILD) Wins EU Trodelvy Approval, Is The Stock Fully Priced?"
              },
              {
                "id": 141361777,
                "url": "https://finnhub.io/api/news?id=26a274b4663e6583598a0897691bb36628bfe157346ac47fe0cb44aa222fb86f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NasdaqGS:GILD) received expanded European Commission approval for Trodelvy in combination with Keytruda as a first-line treatment for metastatic triple-negative breast cancer across PD-L1 status in Europe. The decision establishes Trodelvy plus Keytruda as the first antibody-drug conjugate and immunotherapy combination approved for first-line metastatic TNBC across the European Union. The ruling broadens Trodelvy’s addressable patient population in Europe and further...",
                "category": "company",
                "datetime": 1787822157,
                "headline": "What Does Gilead Sciences (GILD) Gain From Its Expanded EU Breast Cancer Approval?"
              },
              {
                "id": 141329551,
                "url": "https://finnhub.io/api/news?id=320a5de29203b8e44f2edf5548e3915f957e76feed78625c85f5fe1da7b57b64",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217679967/image_2217679967.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.",
                "category": "company",
                "datetime": 1787818087,
                "headline": "GSK: Still One Of My Top Healthcare Picks"
              },
              {
                "id": 141361769,
                "url": "https://finnhub.io/api/news?id=a62de737e1687e03bf446db8e7e01199400c94b7a265a4769397a969754be954",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., August 26, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",
                "category": "company",
                "datetime": 1787778300,
                "headline": "Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences"
              },
              {
                "id": 141361770,
                "url": "https://finnhub.io/api/news?id=a320137b881059faa6f5802c7ae99ce34093959b0f1535f570b1397d695e77ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.",
                "category": "company",
                "datetime": 1787755800,
                "headline": "Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting"
              },
              {
                "id": 141361778,
                "url": "https://finnhub.io/api/news?id=892db49a4f0936d45bd06bdac65644c2feae9e039b7f207cbdbbea24bcb0dd72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Vivace Therapeutics has appointed Craig Gibbs as President and CEO as the company prepares to advance its lead candidate, VT3989, into a pivotal Phase 3 registrational trial. The clinical-stage biopharmaceutical company also named Ellen Lubman as Chief Business and Strategy Officer and...",
                "category": "company",
                "datetime": 1787754540,
                "headline": "Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug"
              },
              {
                "id": 141361185,
                "url": "https://finnhub.io/api/news?id=4742b1dcb34b8cd149f0c6c130850489b3febb0b66b576d8d4ea74b2416b4af2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Its growth profile stands well above major sector peers.",
                "category": "company",
                "datetime": 1787689810,
                "headline": "Eli Lilly Is Pulling Away From the Rest of Healthcare"
              },
              {
                "id": 141361780,
                "url": "https://finnhub.io/api/news?id=e1821998a1b38e6d1fba6cd2ebcc2f3d680182d3d5006513c4c72a002c82bdb6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "These healthcare leaders are unlikely to suspend their dividend programs.",
                "category": "company",
                "datetime": 1787685604,
                "headline": "3 Dividend Stocks to Hold for the Next 10 Years"
              },
              {
                "id": 141317572,
                "url": "https://finnhub.io/api/news?id=05fe13efd00b832cb05a9e82c7065b3ff442b549f68844f834dfbd8fc2100eea",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787664917,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141361781,
                "url": "https://finnhub.io/api/news?id=e427c5cb5e894736084936cc452ce69b31f9f066d70e5ac9f993dc5e0d3345e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.",
                "category": "company",
                "datetime": 1787659844,
                "headline": "3 Unprofitable Stocks with Questionable Fundamentals"
              },
              {
                "id": 141361771,
                "url": "https://finnhub.io/api/news?id=f85a11190d367d2206a23cbaa12c328d93cd87964809faa039fe8e662d6690c5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The European Commission on Monday authorized Trodelvy combined with Merck’s (MRK) Keytruda for certain adults with previously untreated advanced or metastatic triple-negative breast cancer.",
                "category": "company",
                "datetime": 1787605476,
                "headline": "GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict"
              },
              {
                "id": 141361773,
                "url": "https://finnhub.io/api/news?id=19be9fb0641f47f677017906d03a8be49393219050392f373b002359335b144f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Gamgertamig is being developed by Lakefro",
                "category": "company",
                "datetime": 1787605260,
                "headline": "U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus"
              },
              {
                "id": 141361782,
                "url": "https://finnhub.io/api/news?id=adf2caf0c31903f8886028cd52d5763d787af7e0149f9899a3ca70bc853a9170",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "A buyback funded by one oncology drug is concentrating each holder's claim while the next franchise waits on a regulatory decision.",
                "category": "company",
                "datetime": 1787600170,
                "headline": "Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition"
              },
              {
                "id": 141316530,
                "url": "https://finnhub.io/api/news?id=687e8c3370297efdb6cc11f61fe1f67d6aefb3f1c1a85980fea210318940ae2e",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 15.54%. Currently, Gilead Sciences has a market capitalization of",
                "category": "company",
                "datetime": 1787595329,
                "headline": "$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141361772,
                "url": "https://finnhub.io/api/news?id=b6f610dc48e1b8168f8f3af9ba66fdd7ac667a5327cf5ceb0de16699090c76d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., August 24, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive sco",
                "category": "company",
                "datetime": 1787571060,
                "headline": "European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status"
              },
              {
                "id": 141311089,
                "url": "https://finnhub.io/api/news?id=345eb2ad182935027f953cdde25a4e6c367af7c0b9c43f9de41366c79dcbf5ff",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the",
                "category": "company",
                "datetime": 1787553239,
                "headline": "Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer"
              },
              {
                "id": 141361783,
                "url": "https://finnhub.io/api/news?id=f83c51d132a14fd608a768b171d8ff973a57061c2b9939a8b3f399aabfd5c9f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) produced an unusual earnings report in fiscal Q2 2026. Its commercial portfolio delivered double-digit growth, and yet the company posted one of the largest quarterly losses in its recent history. So where did the disconnect come from? It was created by more than $11 billion in acquired research and development expenses […]",
                "category": "company",
                "datetime": 1787533875,
                "headline": "Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?"
              },
              {
                "id": 141278704,
                "url": "https://finnhub.io/api/news?id=22892713c976d04ea1571779ad51eaf32a02a67173f8e9b9bd0bca16a08af077",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.",
                "category": "company",
                "datetime": 1787326126,
                "headline": "Making Drugs With AI: Biopharma Giants Gear Up For New Arena"
              },
              {
                "id": 141278985,
                "url": "https://finnhub.io/api/news?id=88d90bc9320ccde44fdd56c656e43567cb7d12cee27fda40ea4140cb5865a12d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In August 2026, Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead's global antibody-drug conjugate clinical development programs across multiple oncology indications. The partnership highlights how integrating AI-native computational pathology with clinical outcomes may help standardize biomarker assessment and refine precision medicine efforts in Gilead's oncology portfolio. Next, we'll examine how...",
                "category": "company",
                "datetime": 1787213548,
                "headline": "Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?"
              },
              {
                "id": 141278940,
                "url": "https://finnhub.io/api/news?id=9a2603125a2f48fe8376f1066a9191f9e8681072046af9394729dc15c8aa5d23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "These stocks can be safe-haven investments to hide out in amid market turmoil.",
                "category": "company",
                "datetime": 1787155618,
                "headline": "Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022"
              },
              {
                "id": 141278987,
                "url": "https://finnhub.io/api/news?id=c97b2ccd97ddfa672c60e63652ba2e8437994be90f671596a70688e6b4a7bd42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%",
                "category": "company",
                "datetime": 1787154240,
                "headline": "Biotech Stocks Are Booming. What This Top Fund Is Buying Now."
              },
              {
                "id": 141265012,
                "url": "https://finnhub.io/api/news?id=6306299bf8c0083ad7ed7398a1dda29d79bf659716d1cdeed57bf18c43632e5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platformThe broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo...",
                "category": "company",
                "datetime": 1787139000,
                "headline": "HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global \"Best of the Best\" in Life Sciences Innovation"
              },
              {
                "id": 141278978,
                "url": "https://finnhub.io/api/news?id=454646636487a8c60aa5f5644f1fbdb2f5625aec11cea6ea7b024d12cf3e8c77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.",
                "category": "company",
                "datetime": 1787081040,
                "headline": "Is Gilead's Expanding HIV Portfolio a Growth Catalyst?"
              },
              {
                "id": 141278979,
                "url": "https://finnhub.io/api/news?id=d3e9c5bdc656ca3d7bf229884ae9e28d795552139bdbc2ccbd47b290ac9b7614",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.",
                "category": "company",
                "datetime": 1787050680,
                "headline": "Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited."
              },
              {
                "id": 141275702,
                "url": "https://finnhub.io/api/news?id=dd1ad631c87733fc3297a6c3232ebe953f9c2a30eb27e40eb66a8c38d5c3ac84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Prista Charuworn, MD, as Chief Medical Officer. Dr. Charuworn completed fellowships in gastroenterology and transplant hepatology at Stanford and has extensive",
                "category": "company",
                "datetime": 1787040000,
                "headline": "Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer"
              },
              {
                "id": 141278980,
                "url": "https://finnhub.io/api/news?id=60d2e482a6b0f07879855e8a46f549a5e3da002b05959a29c10e9a57ce6a2819",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the company's revenue. The decision blocks a group of companies from importing cheaper foreign versions of Gilead's top HIV drug and selling them to American patients. For a company that relies heavily on a ...",
                "category": "company",
                "datetime": 1786995180,
                "headline": "Gilead yanks out a thorn in its side in major court ruling"
              },
              {
                "id": 141278981,
                "url": "https://finnhub.io/api/news?id=2c9488ba458762ecbb23697b611d414673df1bb818e4898b2bafdcfb930a3bba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "apid clinical validation of antibody-drug conjugates (ADCs) and renewing interest in targeted radioimmunoconjugates highlighted by commercial momentum and patent consolidation from Roche/Genentech, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Pfizer, and Hengrui are driving intense global competition across therapeutic oncology. With approximately 15 ADCs approved worldwide, over 200 candidates in clinical trials, and more than 400 in development, this study analyzes 3,761 patent families to ma",
                "category": "company",
                "datetime": 1786964340,
                "headline": "Cancer & Antibody Conjugates Patent Landscape Report: Evaluating 3,761 Patent Families, Linker-Payload Technologies, and Strategies of Roche, Daiichi Sankyo, Gilead, and AstraZeneca"
              },
              {
                "id": 141278982,
                "url": "https://finnhub.io/api/news?id=cac2d100fab17e42937d15e1d65f3bfe38566449db84ed56b8a8ff7d50b52438",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500’s 13.1% gain. This might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1786916700,
                "headline": "Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?"
              },
              {
                "id": 141231093,
                "url": "https://finnhub.io/api/news?id=bf969ae5433639631187e797478ea95797c83f58a50556484d4e9edbc7d0e2a7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2289235924/image_2289235924.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Assembly Biosciences' key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC. Read why ASMB stock is a Buy.",
                "category": "company",
                "datetime": 1786867200,
                "headline": "Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal"
              },
              {
                "id": 141278989,
                "url": "https://finnhub.io/api/news?id=99a16f1020ceb8843056791f9d4e741619efc08ba95442d9aba40672f453a379",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)’s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies’ 2022 collaboration. That broader agreement spans three programs, including clinical-stage CD123 x CD3 […]",
                "category": "company",
                "datetime": 1786758603,
                "headline": "Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?"
              },
              {
                "id": 141278993,
                "url": "https://finnhub.io/api/news?id=ff3b38de028e7e50709dc758615495185b16f0a856ed5354d7485d956a6faf10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "A federal appeals court ruled Thursday that international versions of Gilead's HIV drug Biktarvy differ materially from FDA-regulated U.S. versions",
                "category": "company",
                "datetime": 1786732471,
                "headline": "Gilead wins appeals court ruling against overseas drug imports"
              },
              {
                "id": 141278992,
                "url": "https://finnhub.io/api/news?id=dd9febaaffadd17c6453617b941b5caf27cdeb0d05ef7fba593bec5de3ada72d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...",
                "category": "company",
                "datetime": 1786730820,
                "headline": "BofA biotech scorecard: Two buys and odd one out"
              },
              {
                "id": 141217771,
                "url": "https://finnhub.io/api/news?id=19549d5f0f2b9e2a691079d96973e87f553e9fde4b23dc31c72b4f2b5c03f932",
                "image": "https://image.cnbcfm.com/api/v1/image/108349765-1786715956264-gettyimages-2207830290-pekiaridis-notitle250404_npeQA.jpeg?v=1786715986&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "A U.S. appeals court has ruled in favor of Gilead Sciences against companies known as alternative funding programs that import medicines from overseas.",
                "category": "company",
                "datetime": 1786710216,
                "headline": "Court rules companies can't import Gilead medications from overseas in blow to AFP health programs"
              },
              {
                "id": 141210900,
                "url": "https://finnhub.io/api/news?id=714f3049974d05781568e54aeb73177aa98de4466863007fedd00cdb53fec5a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across […]",
                "category": "company",
                "datetime": 1786657568,
                "headline": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine"
              },
              {
                "id": 141210934,
                "url": "https://finnhub.io/api/news?id=9e804f414da946d92796585d9eaa31b58e73e97ce4e4cbcf14ceca75f13f6df5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 – – Cash runway projected into 2029, including first $75 million Gilead collaboration extension p",
                "category": "company",
                "datetime": 1786651200,
                "headline": "Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates"
              },
              {
                "id": 141208068,
                "url": "https://finnhub.io/api/news?id=e8474fccde20c15b82a0547c94a1f7892387580eacd890339b4a0c982178c6f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of that progress is now priced into the...",
                "category": "company",
                "datetime": 1786641064,
                "headline": "Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run"
              },
              {
                "id": 141204166,
                "url": "https://finnhub.io/api/news?id=426acb7ffcba4bb7e2f95a99b1f38e58049ec676b419f707a101e0a155435e17",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder returns are above 90%...",
                "category": "company",
                "datetime": 1786612277,
                "headline": "Why Gilead Sciences (GILD) Is Back In The Spotlight"
              },
              {
                "id": 141201191,
                "url": "https://finnhub.io/api/news?id=e0d73969101390814a311fb69caf9aba9dc81604d72c47578522c191dcfd7e71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches—including Trodelvy in breast cancer and Livdelzi in liver disease—for boosting results. CEO Daniel O’Day highlighted, “Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time,” underscoring the im",
                "category": "company",
                "datetime": 1786594860,
                "headline": "5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call"
              },
              {
                "id": 141201192,
                "url": "https://finnhub.io/api/news?id=1128cc54ea79130f88e53db12abde714c6dfe79d5f63b85754f11450003c7395",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead’s oncology pipeline. Gilead is not the only company leaning into AI to reshape drug discovery and development, so...",
                "category": "company",
                "datetime": 1786558430,
                "headline": "Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics"
              },
              {
                "id": 141203345,
                "url": "https://finnhub.io/api/news?id=7442bb6392c2d649788c504adeb341f41a1a3c0e59087bdcfbc48442e7c17c6c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.",
                "category": "company",
                "datetime": 1786545960,
                "headline": "TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses"
              },
              {
                "id": 141193897,
                "url": "https://finnhub.io/api/news?id=a788753f17ba005e5b92695d4ab03dd139ef8c738b86acfe26232f9c67809cd9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/12/Experts-Warn-On-Costly-Attacks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gilead Sciences. Joseph Terranova went for Airbnb.",
                "category": "company",
                "datetime": 1786524297,
                "headline": "KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141201195,
                "url": "https://finnhub.io/api/news?id=fcaccb33a4e8fc647a708fbbb2803077cb481d402a9beb8432de2c71223b8fbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points.",
                "category": "company",
                "datetime": 1786503202,
                "headline": "3 Healthcare Stocks with Open Questions"
              },
              {
                "id": 141201193,
                "url": "https://finnhub.io/api/news?id=5e7672927e7b8294ae4b224ab2aa2221f0378b42a2387f77544aba36543c0c54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies’ 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics. The licensed program incorpora",
                "category": "company",
                "datetime": 1786478700,
                "headline": "MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program"
              },
              {
                "id": 141194904,
                "url": "https://finnhub.io/api/news?id=9ce981519b3a8f9fb15ed2de2cff3f590c6a2daa308648a77608f4c58e8a8b07",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annualized basis producing an average annual return of 11.31%. Currently, Gilead Sciences has a market capitalization of",
                "category": "company",
                "datetime": 1786472144,
                "headline": "If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141200528,
                "url": "https://finnhub.io/api/news?id=43b7700b45a73638a49c042ec837866828a15b04a4cd6839ebd11f3a98553acd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.",
                "category": "company",
                "datetime": 1786453920,
                "headline": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?"
              },
              {
                "id": 140106605,
                "url": "https://finnhub.io/api/news?id=32bf72c36bab6f5e4b49f08cd60e709fadc8a7b3ebe0aae6882cd8560ce7fb27",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "",
                "category": "company",
                "datetime": 1786453281,
                "headline": "Snowflake shares are trading lower. The company announced the appointment of Jonathan Beaulier as Chief Revenue Officer and reaffirmed its FY27 guidance."
              },
              {
                "id": 141201194,
                "url": "https://finnhub.io/api/news?id=18cc2cbdbfa25675647492bc798eab3594e764901de4b17c70671b6b858191e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "TEL AVIV, Israel, August 11, 2026--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting its global antibody-drug conjugate (ADC) clinical development programs.",
                "category": "company",
                "datetime": 1786453200,
                "headline": "Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 92,
            "discarded_article_count": 73
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.3,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(16.8%→6.5%)；跌縮量(近10日5日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 6184020,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 5194760,
              "avg_vol_20": 5286930,
              "avg_vol_30": 6184020,
              "range_pct_10": 0.06470554519715495,
              "range_pct_20": 0.13293280850769973,
              "range_pct_30": 0.16759892272633112,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8400296247424814,
              "dist_to_20d_high": 0.05073746312684371,
              "down_shrink_days": 5,
              "breakout_level_20d": 152.55,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.3860737536052742
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.3329189973068156,
              "turnoverUsdM": 826.50321981,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.GILD",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 138.0534,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 4.7,
            "take_profit_price": 152.4055,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 5.2
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.665837994613631,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.GILD",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 3.3783,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.33
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -19.83
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "強累積",
      "score": 10,
      "value": 0.3124
    },
    "kdj": {
      "d": 58.82,
      "j": 5.51,
      "k": 41.05,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 57.13
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 11654599,
      "recentSlope": -1546100.1,
      "previousSlope": 2863190
    },
    "rsi": 53.04,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 152.1117,
      "position": "SAR喺價上",
      "distancePct": 5.04,
      "previousTrend": "下降"
    },
    "ma50": 137.7352,
    "macd": {
      "macd": 3.086064832113806,
      "trend": "中性偏多",
      "signal": 3.7820250212519877,
      "histogram": -0.6959601891381819
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 145.8587,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.08,
      "score": 6,
      "avgVolume": 5288115,
      "currentVolume": 5707501
    },
    "derived": {
      "ma20": 145.9675,
      "ma50": 137.7352,
      "prevClose": 145.65,
      "avgVolume10": 5239680,
      "avgVolume20": 5288115,
      "changePercent": -0.58,
      "avgVolumeForScore": 5288115
    },
    "ma_cross": {
      "ma20": 145.9675,
      "ma50": 137.7352,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 145.5205,
      "prevMa50": 137.3658,
      "spreadPct": 5.98,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 138.3581,
      "upper": 153.5769,
      "position": "中間"
    },
    "rsi_short": 19.33,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.08
    }
  }
}

{
  "close": 144.81,
  "volume": 5707501,
  "changePercent": -0.58
}